2026-02-27T06:22:40-06:00 2025-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2024-07-01 135644916 BLOOD CANCER UNITED INC BLOO 9149495213 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 GORDON MILLER JR CHIEF FINANCIAL OFFICER 9149495213 2026-02-26 1 0 DEVIN L DUNCAN P01249521 2127589700 2024 2025-03-06 01:10:19Z E ANDERS KOLB MD 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 606472218 0 X BLOODCANCERUNITED.ORG X 1949 NY CURE LEUKEMIA,LYMPHOMA,HODGKIN'S DISEASE, MYELOMA; IMPROVE QUALITY OF LIFE OF PATIENTS AND FAMILIES. 23 19 1390 300000 0 0 338611733 315334371 14932514 16079272 16623882 22273771 -1926070 5011090 368242059 358698504 119474064 124083834 0 0 137851341 154628780 4745743 9354770 49752524 109721024 110061092 371792172 398128476 -3550113 -39429972 602010519 532209663 211058338 171712720 390952181 360496943 X OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. 0 0 127080673 51235960 16079272 A) RESEARCH PROGRAMS:AT BLOOD CANCER UNITED, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE RESEARCH AND DRUG DEVELOPMENT PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 80% OF THE 153 BLOOD CANCER TREATMENT APPROVALS SINCE 2017.AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2025, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO.WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, BLOOD CANCER UNITED FUNDED EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. BLOOD CANCER UNITED IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. IN ADDITION, WHILE BLOOD CANCER UNITED DEDICATES SUBSTANTIAL FUNDING TO ADVANCING NOVEL TREATMENTS FOR BLOOD CANCER, WE RECOGNIZE THAT IT IS EQUALLY IMPORTANT THAT WE COMMIT TO IMPROVING PATIENT ACCESS TO THESE ESSENTIAL THERAPIES. TO THIS END, BLOOD CANCER UNITED ALSO SUPPORTS HEALTH SERVICES RESEARCH WORKING TO IDENTIFY BARRIERS THAT PREVENT CERTAIN PATIENTS FROM BEING ABLE TO ACCESS THE TREATMENT AND CARE THAT THEY NEED AND FINDING ACTIONABLE SOLUTIONS THAT BLOOD CANCER UNITED CAN IMPLEMENT TO OVERCOME THESE BARRIERS AND ADVANCE ITS MISSION. TO DATE, BLOOD CANCER UNITED HAS INVESTED OVER $2 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. OUR SUSTAINED RESEARCH INVESTMENT OVER MULTIPLE DECADES HAS PAID OFF HANDSOMELY. THIS IS BEST DEMONSTRATED BY OUR SEMINAL INVESTMENT IN CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) THERAPY STARTING IN 1990 THAT, SINCE 2017, HAS TRANSLATED INTO 18 FDA-APPROVALS FOR PEDIATRIC AND ADULT B-CELL ACUTE LEUKEMIA, FOR SEVERAL TYPES OF NON-HODGKIN LYMPHOMA, AND MULTIPLE MYELOMA. CAR T-CELL THERAPY HAS IN SOME CASES PRODUCED CURES IN PATIENTS WHO HAVE FAILED ALL OTHER THERAPEUTIC OPTIONS.IN FISCAL YEAR 2025, BLOOD CANCER UNITED SUPPORTED RESEARCH IN THE U.S., CANADA AND SEVERAL OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY $81.3 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS.EQUITY IN ACCESS RESEARCH PROGRAM IN FISCAL YEAR 2022, BLOOD CANCER UNITED LAUNCHED THE EQUITY IN ACCESS RESEARCH PROGRAM, WHICH AIMS TO FUND HEALTH SERVICES RESEARCH THAT WILL GENERATE ACTIONABLE EVIDENCE TO ASSIST BLOOD CANCER UNITED IN ADVOCATING FOR CHANGES IN HEALTHCARE POLICY, DEVELOPING PATIENT-FACING PROGRAMS, AND FOSTERING PRACTICE CHANGE TO EXTEND AND IMPROVE THE LIVES OF ALL BLOOD CANCER PATIENTS. EQUITY IN ACCESS HAS AWARDED NEARLY $18 MILLION TO RESEARCHERS ADDRESSING CRITICAL ISSUES SUCH AS THE COST OF ORAL ANTICANCER MEDICATIONS, THE ROLE OF HEALTH INSURANCE IN FINANCIAL HARDSHIP, AND ACCESS FOR EVERY PATIENT TO CLINICAL TRIALS. BLOOD CANCER UNITED RECOGNIZES THE CRITICAL NEED FOR HIGH-QUALITY EVIDENCE ON INTERVENTIONS TO INCREASE PARTICIPATION IN THERAPEUTIC CANCER CLINICAL TRIALS, WHICH ARE CONSIDERED HIGH-QUALITY CANCER CARE, PARTICULARLY AMONG UNDERREPRESENTED GROUPS (E.G., PEOPLE WHO HAVE LOW INCOMES, PEOPLE WHO LIVE IN RURAL AREAS, ETHNICALLY AND RACIALLY MINORITIZED GROUPS). IN FISCAL YEAR 2025 ALONE, EQUITY IN ACCESS AWARDED NEARLY $5 MILLION TO RESEARCHERS WHO WILL IMPLEMENT AND EVALUATE NOVEL INTERVENTION APPROACHES DESIGNED TO INCREASE THERAPEUTIC CLINICAL TRIAL ENROLLMENT. THERAPY ACCELERATION PROGRAM (TAP)TAP IS BLOOD CANCER UNITED'S MISSION-DRIVEN, STRATEGIC VENTURE PHILANTHROPY INITIATIVE THAT SEEKS TO ACCELERATE THE DEVELOPMENT OF INNOVATIVE BLOOD CANCER THERAPEUTICS AND CHANGE THE STANDARD OF CARE, WHILE ALSO GENERATING A RETURN ON INVESTMENT TO CONTINUE TO SUPPORT ITS MISSION. TAP COLLABORATES WITH BIOTECH COMPANIES TO SUPPORT THE DEVELOPMENT OF NOVEL PLATFORMS AND FIRST-IN-CLASS ASSETS ADDRESSING UNMET MEDICAL NEEDS, EMERGING PATIENT POPULATIONS AND EVEN RARE BLOOD CANCERS.ESTABLISHED IN 2007, TAP HAS INVESTED MORE THAN $115 MILLION IN OVER 50 BIOTECH COMPANY PROJECTS. SINCE 2017, FIVE TAP-SUPPORTED THERAPIES HAVE BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) OR INCLUDED IN THE NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES. CURRENTLY, THERE ARE OVER 30 ACTIVE CLINICAL STUDIES WITH TAP-SUPPORTED THERAPIES, INCLUDING SEVERAL REGISTRATION-ENABLING CLINICAL STUDIES IN BLOOD CANCER THAT COULD LEAD TO MORE FDA APPROVALS.IN FISCAL YEAR 2025, TAP MADE INVESTMENTS IN FIVE BIOTECH COMPANIES THAT INCLUDED THREE EXISTING BIOTECH PARTNERS AND TWO NEW UP-AND-COMING BIOTECH COMPANIES, TO HELP THEM NAVIGATE THE DRUG DEVELOPMENT LANDSCAPE AND TO SUPPORT CLINICAL TRIALS FOR BLOOD CANCER PATIENTS. SEVERAL TAP PARTNER COMPANIES ARE BASED IN EUROPE AND NOW, WITH HELP FROM TAP, THESE COMPANIES ARE RUNNING CLINICAL TRIALS IN THE US. TAP CONTINUES TO EXPAND ITS REACH AND IMPACT BY LEVERAGING ITS UNIQUE EXPERTISE TO ATTRACT MORE COMPANIES AND INVESTORS TO BLOOD CANCER DISEASES, AND TO EXPAND THE TAP INVESTMENT CAPACITY TO SUPPORT THE MOST PROMISING ASSETS.CLINICAL TRIALSBEAT AML MASTER TRIALBEGINNING NOVEMBER 2016, BLOOD CANCER UNITED LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. IN FISCAL YEAR 2025, 135 PATIENTS ENROLLED IN A SUB-STUDY UNDER THE BEAT AML MASTER TRIAL. 123558480 72847874 B) PATIENT & COMMUNITY SERVICES:AN ESTIMATED 1.7 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA, MYELOMA, MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE NEOPLASMS. BLOOD CANCER UNITED OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OFPATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. BLOOD CANCER UNITED IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH BLOOD CANCER UNITED STAFF TO REVIEW ALL OF THE INFORMATION BLOOD CANCER UNITED PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE BLOOD CANCER UNITED WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS.FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND ALLEVIATE THE BURDENS FELT BY PATIENTS COPING WITH BLOOD CANCER, BLOOD CANCER UNITED PROVIDED 69,120 GRANTS TOTALING OVER $162M IN ASSISTANCE AWARDED. THE MAJORITY, $153M, SUPPORTED PATIENTS' INSURANCE PREMIUMS, TREATMENT-RELATED CO-PAYS, AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, BLOOD CANCER UNITED RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH BLOOD CANCER UNITED TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2025, BLOOD CANCER UNITED AWARDED 35,302 GRANTS THROUGH ITS CO-PAY ASSISTANCE PROGRAM. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM BLOOD CANCER UNITED AWARDED 270 GRANTS EACH IN THE AMOUNT OF $2,500 FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM BLOOD CANCER UNITED AWARDED 2,040 GRANTS EACH IN THE AMOUNT OF $500 FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, BLOOD CANCER UNITED AWARDED 9,119 GRANTS EACH IN THE AMOUNT OF $500 FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD. LOCAL FINANCIAL ASSISTANCE PROGRAM BLOOD CANCER UNITED AWARDED 989 GRANTS EACH IN THE AMOUNT OF $500 TO COVER NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD, ETC.PATIENT AID PROGRAM BLOOD CANCER UNITED AWARDED ONE-TIME STIPENDS OF $100 TO OVER 20,345 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. PATIENT AID HELENE & MILTON BLOOD CANCER UNITED AWARDED ONE-TIME STIPENDS OF $100 TO 1055 PATIENTS WHO RESIDED IN DESIGNATED ZIP CODES DECLARED FOR INDIVIDUALASSISTANCE BY FEMA, TO ALLEVIATE FINANCIAL HARDSHIP AS A RESULT OF THE HURRICANES. MEDICAL DEBT CASE MANAGEMENT PROGRAM BLOOD CANCER UNITED'S MEDICAL DEBT CASE MANAGEMENT PROGRAM PROVIDES ONE-ON-ONE, PERSONALIZED SUPPORT TO EMPOWER PATIENTS TO ADDRESS THEIR MEDICAL DEBT IN THE FOLLOWING WAYS: ADDRESS FINANCIAL CONCERNS, INCLUDING MANAGING EXISTING MEDICAL DEBT AND PLANNING FOR UPCOMING MEDICAL EXPENSES; IDENTIFY RESOURCES SUCH AS CHARITY CARE ORGANIZATIONS OR MANUFACTURER PATIENT ASSISTANCE PROGRAMS THAT MAY REDUCE THE FINANCIAL BURDEN; ASSIST WITH INSURANCE PLAN EVALUATION AND ENROLLMENT, SUCH AS MEDICAID, MEDICARE, MARKETPLACE PLANS, AND EMPLOYER-SPONSORED HEALTH INSURANCE; NAVIGATE INSURANCE BENEFITS, DENIALS OF CARE, AND OUT-OF-POCKET COSTS; AND PROVIDE SUPPORT WITH CHARITY CARE, NEGOTIATIONS, INVOICE REVIEW, ETC. THE MEDICAL DEBT CASE MANAGEMENT PROGRAM HANDLED 1579 CASES, HELPING IN THE RESOLUTION OF $3.8 MILLION IN MEDICAL DEBT BLOOD CANCER UNITED IS NOT A DEBT FORGIVENESS PROGRAM, DOES NOT PAY OFF MEDICAL DEBT, AND CANNOT ASSIST WITH DEBT THAT IS IN COLLECTIONS. PROGRAM CASE MANAGERS WORK WITH PATIENTS AND OFFER WAYS TO HELP MANAGE CURRENT DEBT AND PREVENT ACCUMULATING MORE. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS IN 2025, THE BLOOD CANCER UNITED SCHOLARSHIP FOR BLOOD CANCER SURVIVORS AWARDED 285 SCHOLARSHIPS EACH UP TO $7,500 IN TUITION SUPPORT FOR VIRTUAL OR IN-PERSON VOCATIONAL, TWO-YEAR, OR FOUR-YEAR UNDERGRADUATE EDUCATION. 28509773 C) PUBLIC HEALTH EDUCATION: BLOOD CANCER UNITED BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, BLOOD CANCER UNITED HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONE-ON-ONE EDUCATION AND SUPPORTTRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) PROVIDE PATIENTS AND CAREGIVERS WITH COMPASSIONATE, COMPREHENSIVE, AND TAILORED DISEASE AND TREATMENT INFORMATION, INCLUDING REFERRALS AND LINKS TO APPROPRIATE EDUCATIONAL RESOURCES AND LITERATURE; PSYCHOSOCIAL SUPPORT INFORMATION FOR ANY POINT IN THEIR TREATMENT JOURNEY; REFERRALS TO RELEVANT LOCAL, STATE AND/OR NATIONAL RESOURCES FOR ASSISTANCE; COVID-19 RELATED INFORMATION AND GUIDANCE; AND FINANCIAL RESOURCE INFORMATION TO COVER COSTS OF TREATMENT, TRAVEL, URGENT NEEDS AND MORE. OVER 28,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE LAST YEAR.FACILITATING CLINICAL TRIAL ACCESSTHE BLOOD CANCER UNITED CLINICAL TRIAL SUPPORT CENTER (CTSC) CONTINUES TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY PROVIDING EDUCATION, IDENTIFYING SUITABLE CLINICAL TRIALS, AND ADDRESSING BARRIERS TO ENROLLMENT. OUR CLINICAL TRIAL NURSE NAVIGATORS ASSISTED 1158 PATIENTS AND TWENTY PERCENT OF THESE PATIENTS ENTERED A TRIAL.OUTREACH TO UNDERSERVED GROUPSWE AUGMENTED EFFORTS TO EXPAND ACCESS TO BLOOD CANCER UNITED SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE BLACK AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL STAFF AND VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS.MOREOVER, WE CONTINUED TO EXPAND PARTNERSHIPS WITH AFFINITY GROUPS, INCLUDING NATIONAL MINORITY QUALITY FORUM, NATIONAL ASSOCIATION OF RURAL HEALTH, HAIRY CELL LEUKEMIA FOUNDATION, THE BALM IN GILEAD, LATINO MEDICAL STUDENTS ASSOCIATION, IN ADDITION TO MAINTAINING RELATIONSHIPS WITH THOSE GROUPS WITH WHICH WE WERE PREVIOUSLY CONNECTED. THE BLOOD CANCER UNITED MYELOMA LINK PROGRAM, LAUNCHED IN FISCAL YEAR 2017, CONTINUED TO GAIN TRACTION.WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN FISCAL YEAR 2025, BLOOD CANCER UNITED REACHED NEARLY 21,000 PEOPLE THROUGH MYELOMA LINK NATIONAL AND REGIONAL EDUCATION AND OUTREACH ACTIVITIES IN 18 CITIES ACROSS THE U.S.IN 2025, BLOOD CANCER UNITED REACHED OVER 20,000 SPANISH-SPEAKING INDIVIDUALS NATIONWIDE THROUGH HEALTHCARE PROFESSIONAL OUTREACH, LOCAL HEALTH FAIRS, COMMUNITY EVENTS, AND OTHER GRASSROOTS ACTIVITIES. OUR NATIONAL SPANISH-LANGUAGE FACEBOOK LIVE SEGMENTS, COVERING TOPICS SUCH AS NUTRITION, MENTAL HEALTH, AND PATIENTS' RIGHTS, GARNERED OVER 1 MILLION VIEWS. WE STRENGTHENED OUR OUTREACH STRATEGY IN PUERTO RICO THROUGH EXPANDED PATIENT REFERRAL COLLABORATIONS, DEEPER HEALTHCARE PROVIDER ENGAGEMENT, AND TARGETED MEDIA PARTNERSHIPS. HIGHLIGHTS INCLUDED IMPROVING REFERRAL PROCESSES WITH MAJOR HOSPITALS, COORDINATING CO-BRANDED EDUCATION WITH THE AMERICAN CANCER SOCIETY, AND PARTNERING WITH BEHEALTHPR TO BROADEN REACH AMONG SPANISH-SPEAKING AUDIENCES. THESE EFFORTS ARE CRITICAL TO ADDRESSING SYSTEMIC ACCESS BARRIERS AND ENSURING EQUITABLE DELIVERY OF INFORMATION, NAVIGATION, AND SUPPORT SERVICES ACROSS THE ISLAND.EDUCATION AND PATIENT CONNECTIONS.OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. BLOOD CANCER UNITED'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, 1,754 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY BLOOD CANCER UNITED'S REGISTERED DIETITIANS. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED 2,065 PATIENTS WITH TRAINED VOLUNTEERS WHO PROVIDE UNDERSTANDING AND SUPPORT. IN ADDITION, MEMBERSHIP IN THE BLOOD CANCER UNITED COMMUNITY - OUR ONLINE SOCIAL NETWORK - WAS 24,239, AN INCREASE OF 6% OVER FISCAL YEAR 2024. 16653111 BLOOD CANCER UNITED SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. VARYING FORMATS ARE OFFERED TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT HTTPS://BLOODCANCERUNITED.ORG/RESOURCES/HEALTHCARE-PROFESSIONALSIN FY 2025:-BLOOD CANCER UNITED PROVIDED 22 CME/CE-GRANTING LIVE EDUCATIONAL PROGRAMS, WITH 2,266 HEALTHCARE PROFESSIONALS IN ATTENDANCE. IN ADDITION, 48 VIRTUAL LECTURES WERE PRESENTED WITH OVER 66,000 PARTICIPANTS.- OVER 33,000 PATIENTS AND PROFESSIONALS PARTICIPATED IN LIVE EDUCATION PROGRAMS DELIVERED VIRTUALLY AS WELL AS DELIVERED IN PERSON, LOCALLY AND REGIONALLY.--THERE WERE OVER 214,000 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, VIRTUAL LECTURES AND VIDEOS AND OVER 75,500 PODCAST DOWNLOADS. OVER 856,000 BOOKLETS AND FACT SHEETS WERE EITHER DOWNLOADED OR ORDERED IN HARD COPY. 16653111 295802037 1 1 0 1 0 0 0 1 1 1 1 0 0 0 1 1 0 1 0 1 1 1 0 1 1 0 0 1 1 1 0 0 0 0 1 0 1 0 1 0 0 0 1 1 1 0 0 0 1 397 0 1 1390 1 0 1 CA PL 0 0 0 1 1 0 0 0 0 0 0 X 23 19 0 0 1 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AK AL AR AZ CA CO CT DE DC FL GA HI ID IL IN KS KY LA MA MD ME MI MN MO MS NH NJ NM NE NY OH OK OR PA PR RI SC TN UT VA WA WI WV X X GORDON MILLER JR 9148218935 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 ALESSANDRA TOCCO CHAIR 4.00 0.00 X X 0 0 0 FREDA WANG VICE CHAIR 4.00 0.00 X X 0 0 0 MARLA PERSKY SECRETARY/TREASURER 4.00 0.00 X X 0 0 0 JANICE GABRILOVE MD AT LARGE 4.00 0.00 X X 0 0 0 LEROY BALL BOD MEMBER 4.00 0.00 X 0 0 0 RICHARD BAGGER BOD MEMBER 4.00 0.00 X 0 0 0 MARK BARRENECHEA BOD MEMBER 4.00 0.00 X 0 0 0 RENZO CANETTA BOD MEMBER 4.00 0.00 X 0 0 0 M CASEY CUNNINGHAM BOD MEMBER 4.00 0.00 X 0 0 0 SHARON CASTELLINO BOD MEMBER 4.00 0.00 X 0 0 0 MIKE FARMER BOD MEMBER 4.00 0.00 X 0 0 0 ARI MELNICK BOD MEMBER 4.00 0.00 X 0 0 0 KATHLEEN MERIWETHER BOD MEMBER 4.00 0.00 X 0 0 0 RUBEN MESA BOD MEMBER 4.00 0.00 X 0 0 0 LYNNE O'BRIEN BOD MEMBER 4.00 0.00 X 0 0 0 ALEX OKAFOR BOD MEMBER 4.00 0.00 X 0 0 0 JIM REDDOCH BOD MEMBER 4.00 0.00 X 0 0 0 RICHARD RENDINA BOD MEMBER 4.00 0.00 X 0 0 0 ROBERT ROSEN BOD MEMBER 4.00 0.00 X 0 0 0 RAYNE H ROUCE MD BOD MEMBER 4.00 0.00 X 0 0 0 JEFF SACHS BOD MEMBER 4.00 0.00 X 0 0 0 LILIAN STERN BOD MEMBER 4.00 0.00 X 0 0 0 YVETTE TREMONTI BOD MEMBER 4.00 0.00 X 0 0 0 E ANDERS KOLB PRESIDENT & CEO 40.00 0.00 X 879998 0 50519 GWEN NICHOLS EVP, CHIEF MED OFFICER 40.00 0.00 X 736394 0 45341 GORDON MILLER EVP, CHIEF FIN OFFICER 40.00 0.00 X 648480 0 56317 FLORA COKER POWELL EVP, CHIEF REV OFFICER 40.00 0.00 X 512813 0 59334 MEREDITH FOGEL EVP, GEN COUNSEL - START 09/2024 40.00 0.00 X 312368 0 54903 SHONETTE HARRISON CAREW EVP, CHIEF ADMIN OFF - START 09/2024 40.00 0.00 X 162265 0 367 ORLANDO ASHWORTH EVP, CHIEF PEOPLE - START 10/2024 40.00 0.00 X 95040 0 562 LEE GREENBERGER SVP, CHIEF SCI OFFICER - END 12/2024 40.00 0.00 X 408560 0 45162 SUSAN BROWN SVP, CHIEF SUS OFF END - 11/12/2024 40.00 0.00 X 421797 0 27278 FLORENCE GODFREY SVP, CHIEF EXPERIENCE OFFICER 40.00 0.00 X 406318 0 40820 ELISA WEISS SVP, EDUCATION 40.00 0.00 X 367828 0 45294 ANDREW PERRY SVP, BUS OPS AND TECHNOLOGY 40.00 0.00 X 391677 0 15358 DALE NISSENBAUM FORMER EVP, GEN CNSL - END 05/2024 40.00 0.00 X 547759 0 15807 TROY DUNMIRE FORMER EVP, CF OP OFF - END 01/2024 40.00 0.00 X 263181 0 8453 6154478 0 465515 346 1 1 0 ICON PLC - PHARMACEUTICAL RESEARCH ASSOC 4130 PARKLAKE AVENUE SUITE 400 RALEIGH NC 27612 CLINICAL TRIAL 9616721 PATIENT ADVOCATE FOUNDATION 421 BUTLER FARM RD HAMPTON VA 23666 PAT ASSIST PROC 6765372 MOORE A SERIES LLC 4200 PARLIAMENT PLACE SUITE 300 LANHAM MD 20706 PROFESSIONAL FUNDRAISING 4664047 SALESFORCE 140 E 45TH ST NEW YORK NY 10017 SOFTWARE 4565999 KAPADI 9650 STRICKLAND ROAD SUITE 103-150 RALEIGH NC 27615 CLINICAL TRIAL 3123545 175 355986 139255682 175722703 4274075 315334371 SERVICE REVENUE 810000 16079272 16079272 16079272 19224485 19224485 10803789 10803789 228293867 225244581 3049286 3049286 3049286 16736434 139255682 22529133 -5792699 -5792699 358698504 16079272 0 27284861 43522719 43522719 72847874 72847874 7713241 7713241 3278438 1415470 1459842 403126 18231 18231 119579251 76835715 23453195 19290341 3988177 2479454 886340 622383 18745035 11653810 4165931 2925294 9019648 5607526 2004543 1407579 2123694 1274217 573397 276080 419767 419767 3514398 3514398 9354770 9354770 288407 221500 34288 32619 24169211 16408138 3981350 3779723 7605533 4611440 991591 2002502 14060991 8563768 1398549 4098674 12532741 944969 9309320 2278452 3320960 2361477 432198 527285 10789396 8272676 1228284 1288436 5125715 3602255 726974 796486 1109978 81399 1028579 RESEARCH & DEVELOPMENT 19783112 19783112 MISCELLANEOUS 5217189 4086879 461536 668774 398128476 295802037 52573915 49752524 X 17165765 13280340 0 3885425 3858985 5202537 143907675 96813180 45469673 48116644 5836452 9173907 29554477 19862721 10752233 9691756 354480856 330481970 22812891 24669655 10615299 6785419 316667 116667 3959788 1157928 602010519 532209663 36559192 33217287 155633120 122193676 14667950 14994156 4198076 1307601 211058338 171712720 X 251301743 204762655 139650438 155734288 390952181 360496943 602010519 532209663 X -39429972 9453483 -478749 X 0 1 X 1 0 X 441317494 400540019 357670634 338611733 315334371 1853474251 441317494 400540019 357670634 338611733 315334371 1853474251 444706475 1408767776 16877123 18087763 13066416 18039091 30028274 96098667 1949572918 68730146 0.72260 0.68530 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 1 1062365 0 1 82066 1 33271 1 1926174 0 1 410522 3514398 0 PART II-B, LINE 1: BLOOD CANCER UNITED PARTICIPATES IN A NUMBER OF COALITIONS AND MEMBER ORGANIZATIONS, INCLUDING ALLIANCE FOR A STRONGER FDA, ALLIANCE FOR CHILDHOOD CANCER, ALLIANCE FOR FAIR HEALTHCARE PRICING, CANCER LEADERSHIP COUNCIL, DEFENSE HEALTH RESEARCH CONSORTIUM, MAPRX COALITION, NCSL FOUNDATION FOR STATE LEGISLATURES, ONE VOICE AGAINST CANCER, PARTNERSHIP TO PROTECT COVERAGE, PATIENT QUALITY OF LIFE COALITION, PUBLIC AFFAIRS COUNCIL, AND STATE ACCESS TO INNOVATIVE MEDICINES COALITION. EMPLOYEES IN THE BLOOD CANCER UNITED OFFICE OF PUBLIC POLICY WORK TO ADVANCE THE ORGANIZATION'S PUBLIC POLICY PRIORITIES, DOING SO WITH SUPPORT FROM LOBBYING FIRMS AND ADVISERS RETAINED BY BLOOD CANCER UNITED AND IN PARTNERSHIP WITH VOLUNTEER ADVOCATES. BLOOD CANCER UNITED VOLUNTEER ADVOCATES ENGAGE THEIR LAWMAKERS BY CONDUCTING LETTER-WRITING CAMPAIGNS, SHARING THEIR PERSONAL STORIES, AND CONDUCTING ONE-ON-ONE VISITS IN STATE CAPITOLS AND IN WASHINGTON, D.C. - ALL WITH SUPPORT FROM THE BLOOD CANCER UNITED OFFICE OF PUBLIC POLICY. 0 1 1000000 43274 1043274 0 8277308 750040 421590 14450 8591308 7730391 80666 787363 308062 13050 8277308 7288293 30000 713739 291598 10043 7730391 7381460 1129903 -913685 295324 14061 7288293 5902791 1650 1726314 236177 13118 7381460 0.46350 0.53650 0 0 29554477 19862721 9691756 9691756 CAPITAL LEASE LIABILITY 1307601 1307601 X 374017964 -3049286 7631003 11026150 15607867 358410097 288407 288407 358698504 416711240 7631003 11240168 18871171 397840069 288407 288407 398128476 PART III, LINE 1A: THE BLOOD CANCER UNITED COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT BLOOD CANCER UNITED'S PROGRAMS. PART IV, LINE 1B: BLOOD CANCER UNITED HELD APPROXIMATELY $1 MILLION IN ESCROW ON BEHALF OF IFLI AS PART OF A PASS-THROUGH GRANT AGREEMENT. PART V, LINE 4: BLOOD CANCER UNITED'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT BLOOD CANCER UNITED'S PUBLIC EDUCATION PROGRAMS. PART X, LINE 2: BLOOD CANCER UNITED, BLOOD CANCER UNITED RESEARCH PROGRAMS, INC., AND BLOOD CANCER UNITED RESEARCH FOUNDATION QUALIFY AS CHARITABLE ORGANIZATIONS AS DEFINED BY INTERNAL REVENUE CODE SECTION 501(C)(3) AND, ACCORDINGLY, ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). BLOOD CANCER UNITED'S LIMITED LIABILITY COMPANIES ARE DISREGARDED PASS-THROUGH ENTITIES AND ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). ADDITIONALLY, SINCE THESE ORGANIZATIONS ARE PUBLICLY SUPPORTED, CONTRIBUTIONS QUALIFY FOR THE MAXIMUM CHARITABLE CONTRIBUTION DEDUCTION UNDER THE INTERNAL REVENUE CODE. LLSC IS REGISTERED AS A CHARITABLE ORGANIZATION UNDER THE INCOME TAX ACT (CANADA) AND IS, THEREFORE, NOT SUBJECT TO INCOME TAXES IF CERTAIN DISBURSEMENT REQUIREMENTS ARE MET. BLOOD CANCER UNITED AND ITS RELATED ENTITIES RECOGNIZE THE EFFECT OF TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO BLOOD CANCER UNITED'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THERE WERE NO ENTITIES THAT RECOGNIZED UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2024 AND JUNE 30, 2025. PART XI, LINE 2D - OTHER ADJUSTMENTS: LLS CANADA REVENUE 11,026,150. PART XII, LINE 2D - OTHER ADJUSTMENTS: LLS CANADA EXPENSE 11,240,168. 1 NORTH AMERICA 1 RESEARCH FUNDING RESEARCH GRANTS 1078560 EUROPE RESEARCH FUNDING RESEARCH GRANTS 5115956 CENTRAL AMERICA & CARIBBEAN INVESTMENTS INVESTMENTS 15082741 EAST ASIA & THE PACIFIC RESEARCH FUNDING RESEARCH GRANTS 1518725 EUROPE INVESTMENTS INVESTMENTS 6568415 1 0 0 0 1 0 29364397 0 29364397 EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 249069 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 120000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 150000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 249656 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 78600 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 999960 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 750000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 125000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 200000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 650000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 231171 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 246719 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 850000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 175000 WIRE PAYMENT 0 ACCRUAL EUROPE THERAPY ACCELERATION 325152 WIRE PAYMENT 0 FMV EUROPE THERAPY ACCELERATION 501880 WIRE PAYMENT 0 FMV EUROPE THERAPY ACCELERATION 811034 WIRE PAYMENT 0 FMV 18 3 1 0 1 1 0 0 PART I, LINE 2: FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. BLOOD CANCER UNITED PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL BLOOD CANCER UNITED RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS. X X X X X X X 1 MOORE A SERIES LLC 4200 PARLIAMENT PLACE SUITE 300 LANHAM MD 20706 DIRECT MAIL 0 0 4664047 -4664047 4664047 -4664047 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY DC PR LAKE TAHOE CYCLE 3086769 2557137 529632 108347 222101 6315 174169 194052 MANHATTAN WALK 2925993 2652887 273106 21124 236678 941 134 14747 285 149979354 134045658 15933696 1882792 13848046 571319 1807031 3441337 155992116 139255682 16736434 2012263 14306825 578575 1981334 3650136 22529133 -5792699 SCHEDULE G, PART I, LINE 2B, COLUMN (V) BLOOD CANCER UNITED USED MOORE, A SERIES LLC FOR IT'S NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. 1 SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH PO BOX 026338 NEW YORK NY 10087 131924236 501(C)(3) 2513800 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS AT AUSTIN 101 E 27TH ST AUSTIN TX 78712 746000203 GOVT 250000 0 ACCRUAL RESEARCH GRANT UNC LINEBERGER COMPREHENSIVE CANCER CENTER 104 AIRPORT DRIVE CHAPEL HILL NC 27599 566001393 501(C)(3) 70000 0 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 10889 WILSHIRE BLVD LOS ANGELES CA 90024 956006143 GOVT 70000 0 ACCRUAL RESEARCH GRANT FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 237156071 501(C)(3) 1550000 0 ACCRUAL RESEARCH GRANT ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10461 472209056 501(C)(3) 943343 0 ACCRUAL RESEARCH GRANT SOLU THERAPEUTICS 15 NECCO STREET BOSTON MA 02210 922327975 499999 0 FMV THERAPY ACCELERATION BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953432210 501(C)(3) 375000 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVENUE SOUTH SUITE 1170 AB BIRMINGHAM AL 35294 636005396 GOVT 125000 0 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM ST SAN FRANCISCO CA 94103 946036493 501(C)(3) 945000 0 ACCRUAL RESEARCH GRANT OSU FOUNDATION 1960 KENNY ROAD 4TH FLOOR COLUMBUS OH 43210 316025986 501(C)(3) 579132 0 ACCRUAL RESEARCH GRANT THE OHIO STATE UNIVERSITY 1960 KENNY ROAD 4TH FLOOR COLUMBUS OH 43210 316025986 GOVT 296867 0 ACCRUAL RESEARCH GRANT INDIANA UNIVERSITY 2101 E COLISEUM BLVD FORT WAYNE IN 46805 356001673 501(C)(3) 504297 0 ACCRUAL RESEARCH GRANT GEORGE WASHINGTON UNIVERSITY 2121 I ST NW WASHINGTON DC 20052 530196584 501(C)(3) 250000 0 ACCRUAL RESEARCH GRANT MAINE MEDICAL CENTER 22 BRAMHALL STREET PORTLAND ME 04102 010238552 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT RUTGERS UNIVERSITY 3 RUTGERS PLAZA NEW BRUNSWICK NJ 80901 226001086 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT OREGON HEALTH & SCIENCE UNIVERSITY CANCER INSTITUTE 3181 SW SAM JACKSON PARK ROAD PORTLAND OR 97239 237083114 501(C)(3) 190000 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF FLORIDA 33 TIGERT HALL GAINESVILLE FL 32611 596002052 GOVT 2009874 0 ACCRUAL RESEARCH GRANT VAN ANDEL RESEARCH INSTITUTE 333 BOSTWICK AVE NE GRAND RAPIDS MI 49503 522000820 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER 333 COTTMAN AVENUE PHILADELPHIA PA 19111 232003072 501(C)(3) 620000 0 ACCRUAL RESEARCH GRANT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINATTI OH 45229 310833936 501(C)(3) 500541 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF PENNSYLVANIA DEPARTMENT OF MEDICINE 3451 WALNUT STREET FRANKLIN BLDG PHILADELPHIA PA 19104 231352685 501(C)(3) 104214 0 ACCRUAL RESEARCH GRANT PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET FRANKLIN BLDG P-221 PHILADELPHIA PA 19104 231352685 GOVT 640000 0 ACCRUAL RESEARCH GRANT THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 350 COMMUNITY DR MANHASSET NY 11030 112673595 501(C)(3) 250000 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF PITTSBURGH 4200 FIFTH AVE PITTSBURGH PA 10526 250965591 GOVT 120000 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES 4301 WEST MARKHAM ST LITTLE ROCK AR 72205 716046242 GOVT 250000 0 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 5197687 0 ACCRUAL RESEARCH GRANT THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 450 SERRA MALL STANFORD CA 94305 941156365 501(C)(3) 2257440 0 ACCRUAL RESEARCH GRANT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 911156519 501(C)(3) 249999 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF WISCONSIN AT MADISON 500 LINCOLN DR MADISON WI 53715 396006492 GOVT 73600 0 ACCRUAL RESEARCH GRANT DURHAM VA MEDICAL CENTER 508 FULTON STREET DURHAM NC 27705 741612229 501(C)(3) 500000 0 ACCRUAL RESEARCH GRANT NEW YORK COLUMBIA UNIVERSITY MEDICAL CENTER 535 W 116TH ST NEW YORK NY 10027 135598093 501(C)(3) 1173600 0 ACCRUAL RESEARCH GRANT AURON THERAPEUTICS 55 CHAPEL ST NEWTON MA 02458 823865673 500000 0 FMV THERAPY ACCELERATION NYU GROSSMAN SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562309 501(C)(3) 245940 0 ACCRUAL RESEARCH GRANT JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 575 LEXINGTON AVE NEW YORK NY 10022 131623978 501(C)(3) 2115000 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF CHICAGO 5841 S MARYLAND AVE MC6092 CHICAGO IL 60637 362177139 GOVT 123600 0 ACCRUAL RESEARCH GRANT RHODE ISLAND HOSPITAL 593 EDDY STREET PROVIDENCE RI 02903 050258954 501(C)(3) 125000 0 ACCRUAL RESEARCH GRANT THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 501(C)(3) 155000 0 ACCRUAL RESEARCH GRANT NORTHWESTERN UNIVERSITY 633 CLARK AVE EVANSTON IL 60208 362167817 501(C)(3) 157406 0 ACCRUAL RESEARCH GRANT VERSITI BLOOD CENTER OF WISCONSIN 638 N 18TH ST MILWAUKEE WI 53233 390807235 501(C)(3) 37500 0 ACCRUAL RESEARCH GRANT HOUSTON METHODIST RESEARCH INSTITUTE 6670 BERTNER AVENUE HOUSTON TX 77030 870721923 501(C)(3) 500000 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF SOUTHERN CALIFORNIA 700 CHILDS WAY LOS ANGELES CA 90089 951642394 GOVT 239560 0 ACCRUAL RESEARCH GRANT WASHINGTON UNIVERSITY IN ST LOUIS 700 ROSEDALE AVENUE ST LOUIS MO 63112 430653611 501(C)(3) 2252023 0 ACCRUAL RESEARCH GRANT ATRIUM HEALTH FOUNDATION 7800 PROVIDENCE RD CHARLOTTE NC 28226 566060481 501(C)(3) 125110 0 ACCRUAL RESEARCH GRANT TEXAS A&M UNIVERSITY HEALTH SCIENCE CENTER 8441 RIVERSIDE PKWY BRYAN TX 77807 742907553 GOVT 250000 0 ACCRUAL RESEARCH GRANT THE MEDICAL COLLEGE OF WISCONSIN 8701 W WATERTOWN PLANK RD MILWAUKEE WI 53226 390806261 GOVT 375000 0 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0009 LA JOLLA CA 92093 956006144 GOVT 370000 0 ACCRUAL RESEARCH GRANT THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA MEDICAL CENTER OFFICE OF RESEARCH SERVICES PHILADELPHIA PA 19104 231352685 GOVT 1069925 0 ACCRUAL RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 253000 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA AT DAVIS ONE SHIELDS AVE DAVIS CA 95616 946036494 GOVT 250000 0 ACCRUAL RESEARCH GRANT YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06520 060646973 501(C)(3) 664225 0 ACCRUAL RESEARCH GRANT BAYLOR COLLEGE OF MEDICINE PO BOX 301207 DALLAS TX 75303 741613878 501(C)(3) 370000 0 ACCRUAL RESEARCH GRANT EMORY UNIVERSITY PO BOX 935084 ATLANTA GA 31193 582137993 501(C)(3) 1661071 0 ACCRUAL RESEARCH GRANT ST JUDE CHILDREN'S RESEARCH HOSPITAL PO BOX 1000 DEPT 949 MEMPHIS TN 38148 620646012 501(C)(3) 1308000 0 ACCRUAL RESEARCH GRANT VANDERBILT UNIVERSITY MEDICAL CENTER PO BOX 121236 DALLAS TX 75312 620476822 501(C)(3) 424913 0 ACCRUAL RESEARCH GRANT THE BRIGHAM AND WOMENS HOSPITAL INC PO BOX 3149 BOSTON MA 02241 042312909 501(C)(3) 150000 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 22904 237173411 GOVT 999997 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF MIAMI PO BOX 405803 ATLANTA GA 30384 590624458 GOVT 1280887 0 ACCRUAL RESEARCH GRANT BOSTON CHILDREN'S HOSPITAL PO BOX 414413 BOSTON MA 02241 042774441 501(C)(3) 750000 0 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 02241 041564655 501(C)(3) 1073600 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER PO BOX 4266 HOUSTON TX 77210 746001118 GOVT 2518448 0 ACCRUAL RESEARCH GRANT DUKE UNIVERSITY MEDICAL CENTER PO BOX 602651 CHARLOTTE NC 28260 560532129 501(C)(3) 194691 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF COLORADO DENVER ANSCHUTZ MEDICAL CAMPUS PO BOX 6508 AURORA CO 80045 846000555 GOVT 1966500 0 ACCRUAL RESEARCH GRANT H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE PO BOX 742801 ATLANTA GA 30374 593238634 501(C)(3) 1312498 0 ACCRUAL RESEARCH GRANT THE CHILDREN'S HOSPITAL OF PHILADELPHIA PO BOX 8500 PHILADELPHIA PA 19178 231352166 501(C)(3) 284000 0 ACCRUAL RESEARCH GRANT MAYO CLINIC ROCHESTER PO BOX 860334 MINNEAPOLIS MN 55486 416011702 501(C)(3) 125000 0 ACCRUAL RESEARCH GRANT VETERANS HEALTH FOUNDATION UNIVERSITY DR PITTSBURGH PA 15240 251666090 501(C)(3) 50000 0 ACCRUAL RESEARCH GRANT 65 2 COPAY ASSISTANCE CLL 12007 24198796 COPAY ASSISTANCE LYMPHOMA 7712 19535615 COPAY ASSISTANCE MDS 1507 524688 COPAY ASSISTANCE MYELOMA 7297 6469725 COPAY ASSISTANCE MANTEL 722 1526820 COPAY ASSISTANCE WALDENST 470 1127345 COPAY ASSISTANCE AML 5587 8932351 PATIENT TRAVEL ASSISTANCE 2310 1744037 PATIENT AID 35250 9103963 PART I, LINE 2: FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. BLOOD CANCER UNITED PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL BLOOD CANCER UNITED RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: BLOOD CANCER UNITED REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, BLOOD CANCER UNITED HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND OF HELP DEFER SOME OF THESE EXPENSES. BLOOD CANCER UNITED ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: BLOOD CANCER UNITED REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTEN TIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, BLOOD CANCER UNITED ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. BLOOD CANCER UNITED ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. X X X X X 0 0 0 0 0 0 0 1 0 E ANDERS KOLB PRESIDENT & CEO 678834 0 200000 0 1164 0 4982 0 45537 0 930517 0 0 0 GWEN NICHOLS EVP, CHIEF MED OFFICER 466269 0 105142 0 164983 0 17250 0 28091 0 781735 0 0 0 GORDON MILLER EVP, CHIEF FIN OFFICER 404089 0 90964 0 153427 0 17250 0 39067 0 704797 0 0 0 FLORA COKER POWELL EVP, CHIEF REV OFFICER 433238 0 57711 0 21864 0 17250 0 42084 0 572147 0 0 0 DALE NISSENBAUM FORMER EVP, GEN CNSL - END 05/2024 397356 0 0 0 150403 0 5933 0 9874 0 563566 0 0 0 LEE GREENBERGER SVP, CHIEF SCI OFFICER - END 12/2024 346235 0 47558 0 14767 0 17250 0 27912 0 453722 0 0 0 SUSAN BROWN SVP, CHIEF SUS OFF END - 11/12/2024 375110 0 46513 0 174 0 12075 0 15203 0 449075 0 0 0 FLORENCE GODFREY SVP, CHIEF EXPERIENCE OFFICER 343837 0 61550 0 931 0 12220 0 28600 0 447138 0 0 0 ELISA WEISS SVP, EDUCATION 323795 0 43058 0 975 0 17250 0 28044 0 413122 0 0 0 ANDREW PERRY SVP, BUS OPS AND TECHNOLOGY 331055 0 59723 0 899 0 12075 0 3283 0 407035 0 0 0 MEREDITH FOGEL EVP, GEN COUNSEL - START 09/2024 264771 0 46707 0 890 0 16040 0 38863 0 367271 0 0 0 TROY DUNMIRE FORMER EVP, CF OP OFF - END 01/2024 263176 0 0 0 5 0 1464 0 6989 0 271634 0 0 0 SHONETTE HARRISON CAREW EVP, CHIEF ADMIN OFF - START 09/2024 112033 0 50000 0 232 0 0 0 367 0 162632 0 0 0 PART I, LINE 7 BLOOD CANCER UNITED AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO EMPLOYEE PERFORMANCE AND ORGANIZATION TARGETS. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2,PART II, COL (B) (II). SHARON CASTELLINO BOARD MEMBER 150000 GRANTS RESEARCH GRANT ARI MELNICK BOARD MEMBER 1500000 GRANTS RESEARCH GRANT RAYNE ROUCE BOARD MEMBER 300000 GRANTS RESEARCH GRANT SHEENA MEHTA DAUGHTER-IN-LAW OF BOARD MEMBER OF JANICE GABRILOVE 18231 COMPENSATION 0 X 253 4246606 FAIR MARKET VALUE X 3 6379 FAIR MARKET VALUE X VARIOUS OTHER 19 18490 FAIR MARKET VALUE X PRINTED ITEMS 1 2600 FAIR MARKET VALUE 0 1 0 SCHEDULE M - SUPPLEMENTAL INFORMATION PART I, COLUMN B BLOOD CANCER UNITED IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. FORM 990, PART VI, SECTION A, LINE 4 ALL OF BLOOD CANCER UNITEDS BYLAWS AND CHARTERS WERE CHANGED FROM LEUKEMIA AND LYMPHOMA SOCIETY TO BLOOD CANCER UNITED AS PART OF AN ORGANIZATION-WIDE NAME CHANGE. NO OTHER CHANGES WERE MADE. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY THE BLOOD CANCER UNITED'S FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, SENIOR VICE PRESIDENT OF FINANCE, VICE PRESIDENT, CONTROLLER, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C ALL BLOOD CANCER UNITED KEY PERSONS ARE REQUIRED TO COMPLETE ANNUAL CONFLICT OF INTEREST DISCLOSURE STATEMENTS. OTHER LLS REPRESENTATIVES ARE ENCOURAGED TO DISCLOSE POTENTIAL CONFLICTS AND MAY BE REQUIRED TO COMPLETE DISCLOSURE STATEMENTS WHEN REQUESTED. ALL DISCLOSURE STATEMENTS ARE REVIEWED BY THE LEGAL DEPARTMENT AND ESCALATED TO THE AUDIT COMMITTEE FOR EVALUATION AND MANAGEMENT OF ACTUAL OR POTENTIAL CONFLICTS OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE TALENT AND COMPENSATION COMMITTEE, COMPRISED OF INDEPENDENT BOARD MEMBERS, ESTABLISHES COMPENSATION GUIDELINES AND RECOMMENDS CEO COMPENSATION TO THE EXECUTIVE COMMITTEE BASED ON PERFORMANCE EVALUATIONS AND MARKET STUDIES. THE EXECUTIVE COMMITTEE ESTABLISHES CEO PERFORMANCE GOALS AND CONDUCTS EVALUATIONS. THE EXECUTIVE COMMITTEE MAKES FINAL RECOMMENDATIONS TO THE BOARD FOR APPROVAL, WITH ALL DECISIONS DOCUMENTED IN COMMITTEE MINUTES. THE LAST EVALUATION WAS NOVEMBER 2024. FORM 990, PART VI, SECTION C, LINE 19 BLOOD CANCER UNITED MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT BLOODCANCERUNITED.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. FORM 990, PART XI, LINE 9: FOREIGN CURRENCY ADJUSTMENTS -478,749. BEAT AML LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH NY 6984125 712731 BLOOD CANCER UNITED PEDAL BCU LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH NY 11534579 1634650 BLOOD CANCER UNITED TAP BCU LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE -1112729 9770672 BLOOD CANCER UNITED TAP BCU AURON LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED TAP BCU KDAC LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED TAP BCU KURA LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED TAP BCU CONSTELLATION LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED TAP BCU KYMERA LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED TAP BCU MIRAGEN LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED TAP BCU SOLU LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED TAP BCU CROSSBOW LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED TAP BCU X4 LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED MISSION ASSETS LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED MISSION ASSETS - MCG LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED RESEARCH RETURNS LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED JLSA3 RR LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE BLOOD CANCER UNITED THE LLS OF CANADA 804 2 LANSING SQUARE TORONTO CA M2J4P8 BLOOD CANCER RESERACH CA N/A 0 BLOOD CANCER UNITED RESEARCH FOUNDATION 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 133709252 SUPPORTS BLOOD CANCER UNITED DE 501(C)(3) LINE 12A, I BLOOD CANCER UNITED INC 1 BLOOD CANCER UNITED RESEARCH PROGRAMS INC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 133470494 SUPPORTS BLOOD CANCER UNITED DE 501(C)(3) LINE 12A, I BLOOD CANCER UNITED INC 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0